Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, showing its potential as a next-generation treatment in the hyper-competitive market.
The drug known as amycretin showed signs of improving blood sugar levels with side effects generally in line with other powerful obesity medicines, researchers said in a pair of trials published in The Lancet and due to be presented at the American Diabetes Association conference in Chicago. The 24.3% weight loss came over 36 weeks in a study of the shot version of the compound.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.